Peritoneal dialysis

Home dialysis, which includes both peritoneal dialysis and home hemodialysis, allows patients to receive their dialysis treatments at home, gives patients independence and flexibility with their treatment schedules, and is associated with similar or better outcomes and lower costs compared with conventional in-center hemodialysis. Home dialysis modalities are the fastest growing types of dialysis treatments in the United States, and this trend is likely to continue as recent policies provide incentives to dialysis providers and kidney specialists to promote home dialysis.

Baxter has received an FDA clearance for its latest, portable dialysis machine designed to connect directly with electronic medical records for patients’ prescriptions and treatment data. The company’s AK 98 hemodialysis machine is not designed for home use or self-care, but to assist healthcare providers with the logistics of administering multiple treatment sessions per day with the same unit.

TX is the most cost-effective RRT modality, followed in order by PD and HD. The strategy with an increased proportion of incident patients on PD and TX is cost-effective compared with the current practice pattern at the given WTP threshold. The planning for RRT service delivery should incorporate efforts to increase the utilisation of PD and TX in China.

The increasing prevalence of various chronic diseases such as diabetes that results in kidney disorders is a key factor aiding in expansion of the global end stage renal disease market during the forecast period between 2020 to 2030. Elements prompting this infection are diabetes, hypertension, smoking, and mature age. Diabetes is the most widely recognized reason, trailed by (hypertension). To remain alive and treat the ESRD, a patient needs to embrace dialysis or relocate their kidneys. The components fuelling the development of this market are expanding number of kidney patients, a lot of interest in the R&D, presentation of mechanically progressed supplies, for example, counterfeit kidney and low upkeep dialysis hardware.

Mobile health is the health care use of mobile devices, such as smartphones. Mobile health readiness is a prerequisite to successful implementation of mobile health programs. The aim of this study was to examine the status and correlates of mobile health readiness among individuals on dialysis.

A new California law aims to curb what sponsors say is profiteering by dialysis centers. But are there any easy answers?

Quanta Dialysis Technologies is bringing its small, lightweight blood purification system to the U.S., following its commercial launch in the U.K. last year and clinical pilots with the country’s National Health Service. With a new FDA clearance in hand, the British company plans to roll out its portable SC+ hemodialysis machine to a variety of care settings on the other side of the pond. Its modular, cartridge-based design can provide both high-flow modes—for the typical three-times-a-week appointments—or sustained, low-efficiency dialysis treatments for a gentler option.

Small enough to fit on top of a cart or desk, it can be used by healthcare professionals in hospitals as well as moved around skilled nursing facilities, with future water purification add-ons that will allow it to operate without a centralized water system.

Seventy-six of the nephrology trainees completed the survey. The researchers found that regarding the principles of PD, most respondents were moderately confident. However, only 3 and 11 percent had initiated patients on urgent-start PD and observed a PD catheter insertion, respectively. For HHD, the level of confidence was low. Most trainees attended a home dialysis continuity clinic with faculty mentorship.

PD is a safe way of renal replacement therapy to protect patients from COVID‐19 pandemic. The data obtained support that PD is successful and safe during the pandemic. Also, RM‐APD may be a better choice in patients with PD because bone mineral metabolism seems to remain more stable. Moreover, evaluating depression and anxiety at the phone visits may be important for the accurate clinical assessment.

The Homechoice Claria system was cleared for both adults and children. Its interface is available in 38 languages and features step-by-step, voice-activated instructions through an accompanying app to help guide the user through therapy.

PD differs from other dialysis options in that it uses the body’s own abdominal lining (the peritoneum) to clean the blood rather than a synthetic filter (dialyzer). If you choose PD, you’ll need a PD catheter surgically placed, typically through your abdomen. Typically the catheter exit site is allowed to heal for a few weeks, before you begin PD treatments.

Unusually high demand for dialysis to treat acute kidney injury (AKI) in patients hospitalized with COVID-19 led to rapid adoption of acute peritoneal dialysis (PD) programs at some institutions in New York City, according to reports presented at the American Society of Nephrology’s Kidney Week 2020 Reimagined virtual conference.

Fresenius Medical Care North America's (FMCNA) Renal Therapies Group announced today that DELFLEX® peritoneal dialysis solutions in Biofine®, an innovative bag material, has been approved by the U.S. Food and Drug Administration (FDA). The milestone marks another important step in the company's commitment to grow home dialysis through new and improved products.

Urgent-start peritoneal dialysis (PD) in patients with newly diagnosed end-stage renal disease (ESRD) is a well-tolerated alternative to hemodialysis (HD). The primary aim of this study was to identify the demographic and clinical characteristics of ESRD patients, as well as the presurgical, surgical, and postsurgical factors associated with urgent-start PD complications.

This video has information about how to prevent, recognize, and respond to peritonitis, a bacterial or fungal infection of the peritoneum (a silk-like membrane covering the inner lining of the abdomen), which could occur in peritoneal dialysis.

A study conducted in Canada found patients who initiated kidney replacement therapy with home hemodialysis experienced lower risks for both mortality and treatment failure compared with those who had peritoneal dialysis.

The efficacy of peritoneal dialysis (PD) to treat acute kidney injury (AKI) was brought to light after a randomized control trial demonstrated PD is not inferior to intermittent hemodialysis (iHD) for treating acutely ill patients with AKI stage 3 in terms of mortality. Additionally, its ability to be used with minimal infrastructure in place, including the lack of need for water or electricity, made it a novel therapy in many third-world countries.

In Hong Kong where there is a PD first policy, 71% of patients use PD, while in Mexico 61 % of patients use PD largely due to lack of availability of other forms of dialysis. In countries with robust education programs (Australia, New Zealand, Canada) approximately 20-30 % of patients use PD. In contrast, among maintenance dialysis patients in the United States (US), the prevalence of PD reached a low of 6.9% in 2009, although the prevalence increased to 10.1% in 2017. Additionally, the proportion of incident dialysis patients initiating dialysis with PD over the same time period has increased from 6.2% to 10.4%. This in part is due to the bundled payment system introduced in 2011. Critically, although the number of patients treated with PD is increasing in the US, it remains lower than what many nephrologists perceive it should be.

While the Executive Order set forth bold goals to increase home dialysis utilization amongst patients with end stage renal disease (ESRD),1 the COVID-19 pandemic has served as an even greater impetus to allow appropriate patients to dialyze at home. In many areas, the cancellation of elective surgeries has led to delays in getting appropriate accesses created for our ESRD patients. For some, timely access creation was an issue even before the pandemic.